Byung Chan Ahn, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,451, more than ten times the $104 reported in 2019.
Across 256 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$881
- UCB, Inc.$817
- Neurocrine Biosciences, Inc.$451
- Bristol Myers Squibb$413
- Pfizer$266
- Biogen$246
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,66598%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $881 |
| UCB, Inc. | 49 | $817 |
| Neurocrine Biosciences, Inc. | 21 | $451 |
| Bristol Myers Squibb | 23 | $413 |
| Pfizer | 13 | $266 |
| Biogen | 13 | $246 |
| Impel Pharmaceuticals Inc. | 21 | $199 |
| Merz Pharmaceuticals, LLC | 4 | $140 |
| Lundbeck LLC | 5 | $112 |
| Teva Pharmaceuticals USA, Inc. | 4 | $106 |
| Catalyst Pharmaceuticals, Inc. | 6 | $104 |
| SK Life Science, Inc. | 3 | $85 |
| Amgen | 4 | $82 |
| MDD US Operations, LLC | 2 | $81 |
| CSL Behring | 5 | $81 |
| Neurelis, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Genentech USA, Inc. | 4 | $66 |
| Argenx US, Inc. | 3 | $65 |
| Boston Scientific | 1 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Abbott | 2 | $32 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 2 | $25 |
| Microtransponder, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Octapharma USA, Inc. | 1 | $18 |
| Livanova USA, Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$104
How this compares
$4,757 in reported general payments places this provider in the 65th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 49 | $750,287 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $158,569 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $112,713 |
| EliquisApixaban | 20 | $30,743 |
| Emgality PenGalcanezumab-Gnlm | 19 | $17,693 |
| BotoxOnabotulinumtoxina | 13 | $15,638 |
| Lacosamide | 16 | $4,411 |
| Levetiracetam | 70 | $4,162 |
| Baclofen | 69 | $2,801 |
| Pyridostigmine Bromide | 14 | $1,857 |
| Carbamazepine ErCarbamazepine | 12 | $1,737 |
| Memantine Hcl | 51 | $1,595 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 39 | $1,354 |
| AmantadineAmantadine Hcl | 23 | $1,070 |
| Carbamazepine | 16 | $1,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga, Eliquis | $266 | $939,59985 claims |
| CSL BehringPrivigen | $81 | $112,71319 claims |
| AbbVieBotox | $881 | $15,63813 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $38 | $1,85714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 145 neurology providers in Nevada.
Other neurology in Reno
- Melissa BlochReno$883K
- Burton TabaacReno$287K
- G BigleyReno$133K
- Lee GerwitzReno$88K
- Verena SamaraReno$64K
- Frank QuaglieriReno$21K
- Timothy LouieReno$15K
- Yen-Yi PengReno$14K
- Danny TruongReno$12K
- Rolando AniaReno$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.